^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cisplatin

    i
    Other names: L01XA01, L01 XA01, L01-XA01
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    1d
    MEDINDUCTION: Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=14, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | N=36 --> 14 | Unknown status --> Terminated; Toxicities due to the treatment, stop of enrollment
    Enrollment change • Trial termination
    |
    cisplatin • Imfinzi (durvalumab) • docetaxel • 5-fluorouracil
    1d
    A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=854, Recruiting, AbbVie | Trial completion date: Dec 2031 --> Nov 2036 | Trial primary completion date: Dec 2031 --> Nov 2036
    Trial completion date • Trial primary completion date • Adverse events
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • telisotuzumab adizutecan (ABBV-400)
    1d
    A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, The Central Hospital of Lishui City | N=51 --> 30
    Enrollment change • IO biomarker • Circulating tumor DNA
    |
    cisplatin • paclitaxel
    1d
    Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Boehringer Ingelheim
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • HER-2 mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Hernexeos (zongertinib)
    1d
    Comparative Study of Different Doses of Magnesium as a Protective Agent in Nephrotoxicity in Cancer Patients (clinicaltrials.gov)
    P2, N=100, Completed, Tanta University | Enrolling by invitation --> Completed | N=75 --> 100 | Trial completion date: Oct 2024 --> Mar 2025
    Trial completion • Enrollment change • Trial completion date
    |
    cisplatin
    1d
    Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=386, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin
    4d
    Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy (clinicaltrials.gov)
    P2, N=39, Completed, UNC Lineberger Comprehensive Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine
    4d
    Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA) (clinicaltrials.gov)
    P2, N=35, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Mar 2026 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • docetaxel
    4d
    A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P3, N=498, Active, not recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cisplatin • carboplatin • ruzaltatug rezetecan (SHR-A2009)
    4d
    Cisplatin+Pembrolizumab+RT in Vulvar Cancer (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, Massachusetts General Hospital | Trial primary completion date: Dec 2025 --> Apr 2026
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • cisplatin
    4d
    EA2197: Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer (clinicaltrials.gov)
    P2/3, N=186, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: Jun 2029 --> Jul 2028
    Trial primary completion date
    |
    cisplatin • gemcitabine
    5d
    Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301. (PubMed, ESMO Open)
    Early termination limited the ability to draw definitive conclusions on the efficacy of infigratinib as first-line treatment of FGFR2-rearranged CCA. This study illustrates the challenges of powering confirmatory studies in biomarker-selected subpopulations of rare tumors and highlights the need for regulatory collaboration to develop pragmatic frameworks for assessing novel therapies in ultra-rare malignancies.
    P3 data • Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 fusion
    |
    cisplatin • gemcitabine • Truseltiq (infigratinib)